Omega-3 The Overlooked Evidence-Based Therapy for Heart Failure


Full Text via DOI: 10.1016/j.jchf.2022.02.004 Web of Science: 000791269400004

Cited authors

  • O'Keefe JHJ, O'Keefe EL, Lavie CJ


  • mpressive scientific evidence continues to accumulate supporting the use of omega-3 in the treatment and/or prevention of heart failure Failure) trial enrolled 6,975 patients in New York Heart Association functional classes II-IV HF with reduced left ventricular ejection fraction (LVEF) and mean LVEFs of 33%, and randomized them in a double-blind protocol to either placebo or 840 mg of omega-3 fatty acids that consisted of 460 mg/day of eicosapentaenoic acid (EPA) + 380 mg/day of docosahexaenoic acid (DHA).1 After 3.9 years, omega-3 reduced both primary endpoints of the trial, including: 1) death or hospitalization for cardiovascular (CV) reasons by 8% (P = 0.009), with a number needed to treat (NNT) of 44; and 2) death from any cause by 9% (P = 0.041) with NNT of 56. At baseline, the patients in GISSI-HF were already treated with recommended HF therapies, and the benefits from omega-3 were consistent among all prespecified subgroups, including the 50% of the trial participants who had HF caused by ischemic cardiomyopathy and in the nonischemic cardiomyopathy group as well.1 Considering that omega-3 had a placebo-like side effect profile and produced

Publication date

  • 2022

International Standard Serial Number (ISSN)

  • 2213-1779

Number of pages

  • 3

Start page

  • 235

End page

  • 237


  • 10


  • 4